| LncRNA Information | ||||||
|---|---|---|---|---|---|---|
| ID | EL0933 | Name | MR1 | Aliases | HLALS | |
| Species | Homo sapiens | Chromosome | 1 | Start site | 181033425 | |
| End site | 181061938 | Chain | plus | Exon NO. | 8 | |
| Assembly | Ensembl Release 89 | Class | retained intron | NCBI accession | N/A | |
| Ensembl | ENSG00000153029 | Sequence | N/A | |||
| Disease | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source | ||
| Loeys-Dietz syndrome (LDS) | RT-PCR | aortic aneurysm patients | differential expression | interaction | LncRNA AK056155 was differentially expressed in peripheral blood circulating endothelial cells between normal patients and LDS patients by bioinformatics. AK056155 was also overexpressed in aortic aneurysm patients by RT-PCR. | 26617788 | |||
| Interaction | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Interaction target | Level of interaction | Type of interaction | Description | PMID | Source | ||||
| TGF-β1; PI3K inhibitor (LY294002); AKT inhibitor (GDC-0068) | DNA-Protein | regulation | the expression of AK056155 can be enhanced by TGF-β1 in a concentration or time depended manner in HUVECs by RT-PCR. Furthermore, the expression of AK056155 was reduced with treatment of PI3K inhibitor (LY294002) or AKT inhibitor (GDC-0068) in combination with TGF-β1. | 26617788 | |||||